Discontinuing first-line DMT in long-term stable MS led to significantly higher inflammatory disease recurrence, even in younger patients, highlighting risks and informing decisions on treatment cessation. Trial terminated early due to safety concerns.
Do immune checkpoint inhibitors affect the course of multiple sclerosis? A systematic review and meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39555755/
We found a low relapse rate in pwMS following ICI treatment, with no events in older pwMS. The risk of neuroradiological activity appears higher, but mainly occurs in pwMS who...
Immune checkpoint inhibitors (ICIs) in multiple sclerosis (MS) show low relapse rates but higher neuroradiological activity, mainly in those discontinuing disease-modifying treatments, with events occurring within six months of therapy.
A Hypoxia-Inflammation Cycle and Multiple Sclerosis: Mechanisms and Therapeutic Implications - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39569339/
The hypoxia-inflammation cycle could exacerbate neuroinflammation and disease progression. We explore therapeutic approaches that target this cycle, providing information about potential treatments in MS. There are many therapeutic approaches that...
This review highlights the hypoxia-inflammation cycle's role in multiple sclerosis progression, its mechanisms, and potential therapeutic strategies targeting hypoxia-inducible factors, vascular issues, and inflammation to mitigate disease progression.
Antioxidant Therapies in the Treatment of Multiple Sclerosis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39456199/
Several studies have proposed a potential role for oxidative stress in the development of multiple sclerosis (MS). For this reason, it seems tentative to think that treatment with antioxidant substances...
This review highlights the potential role of antioxidants in multiple sclerosis (MS) treatment, summarizing experimental model findings and clinical trials, while emphasizing the need for long-term, large-scale studies to confirm efficacy.
Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39177889/
Multiple sclerosis (MS) is a chronic autoimmune disease characterized by pathological processes of demyelination, subsequent axonal loss, and neurodegeneration within the central nervous system. Despite the availability of numerous disease-modifying...
This review explores current and emerging therapies for multiple sclerosis, focusing on novel targets like monoclonal antibodies, CAR T cell therapy, microglia, ferroptosis, and microbiota-based interventions for holistic management.